Gardasil 9 Dosage/Direction for Use

Posology: The primary vaccination course consists of 3 separate 0.5 ml doses administered according to the following schedule: 0, 2, 6 months.
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.
Alternatively, in individuals 9 through 14 years of age, GARDASIL 9 can be administered according to a 2-dose schedule. The second dose should be administered between 5 and 13 months after the first dose. If the second vaccine dose is administered earlier than 5 months after the first dose, a third dose should always be administered.
The need for a booster dose has not been established.
It is recommended that individuals who receive a first dose of GARDASIL 9 complete the vaccination course with GARDASIL 9 (see Precautions).
Studies using a mixed regimen (interchangeability) of HPV vaccines were not performed for GARDASIL9.
Subjects previously vaccinated with a 3-dose regimen of quadrivalent HPV types 6, 11, 16, and 18 vaccine (GARDASIL), hereafter referred to as qHPV vaccine, may receive 3 doses of GARDASIL 9 (see Pharmacology: Pharmacodynamics under Actions).
Paediatric population (children <9 years of age): The safety and efficacy of GARDASIL 9 in children below 9 years of age have not been established. No data are available (Pharmacology: Pharmacodynamics under Actions).
Method of administration: The vaccine should be administered by intramuscular injection. The preferred site is the deltoid area of the upper arm or in the higher anterolateral area of the thigh.
GARDASIL 9 must not be injected intravascularly, subcutaneously or intradermally. The vaccine should not be mixed in the same syringe with any other vaccines and solution.
For instructions on the handling of the vaccine before administration, see Cautions for Usage.